New antibiotic for resistant klebsiella infections
Part of Infections clinical trials.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for infections caused by a resistant bacteria called Klebsiella pneumoniae. It aims to see how well this drug works against these hard-to-treat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an infection caused by a bacterium called Klebsiella pneumoniae.
- The infection should be in one of these areas: skin, chest, surgical site, or urinary tract.
- The bacteria must be resistant to a group of strong antibiotics called carbapenems.
- The resistance must be due to a specific mechanism called carbapenemase production.
- You cannot have an infection caused by any other type of bacteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new antibiotic (cefiderocol) works against a tough type of Klebsiella pneumoniae bacteria that is resistant to many other antibiotics. It may help find better treatments for serious infections.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
Hear when a new ISOLATION OF KLEB. by Culture on macConkey Agar trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.